Mesenchymal Phenotype Predisposes Lung Cancer Cells to Impaired Proliferation and Redox Stress in Response to Glutaminase Inhibition

• Danielle B. Ulanet,

  Affiliation Agios Pharmaceuticals, Cambridge, Massachusetts, United States of America

  ⨯
• Kiley Couto,

  Affiliation Agios Pharmaceuticals, Cambridge, Massachusetts, United States of America

  ⨯
• Abhishek Jha,

  Affiliation Agios Pharmaceuticals, Cambridge, Massachusetts, United States of America

  ⨯
• Sung Choe,

  Affiliation Agios Pharmaceuticals, Cambridge, Massachusetts, United States of America

  ⨯
• Amanda Wang,

  Affiliation Agios Pharmaceuticals, Cambridge, Massachusetts, United States of America

  ⨯
• Hin-Koon Woo,

  Affiliation Agios Pharmaceuticals, Cambridge, Massachusetts, United States of America

  ⨯
• Mya Steadman,

  Affiliation Agios Pharmaceuticals, Cambridge, Massachusetts, United States of America

  ⨯
• Byron DeLaBarre,

  Affiliation Agios Pharmaceuticals, Cambridge, Massachusetts, United States of America

  ⨯
• Stefan Gross,

  Affiliation Agios Pharmaceuticals, Cambridge, Massachusetts, United States of America

  ⨯
• Edward Driggers,

  Affiliation Agios Pharmaceuticals, Cambridge, Massachusetts, United States of America

  ⨯
• Marion Dorsch,

  Affiliation Agios Pharmaceuticals, Cambridge, Massachusetts, United States of America

  ⨯
• Jonathan B. Hurov

  * E-mail: jonathan.hurov@agios.com

  Affiliation Agios Pharmaceuticals, Cambridge, Massachusetts, United States of America

  ⨯